PITTSBURGH, PA – January 27, 2021 – Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced that Larry Brown, Sc.D., Chief Scientific Officer, and David Steed, M.D., Chief Medical Officer, will present an update on its retinal and optic nerve disease clinical program at the Glaucoma Research Foundation’s 10th Annual Glaucoma 360 Virtual Meeting. The pre-recorded presentation will take place on Saturday, January 30, 2021 during the New Horizon’s Forum and is scheduled for 9:27 AM – 10:07 AM P.T. (12:27 PM – 1:07 PM E.T.) with a live question and answer session. Advance registration is required. In addition, the pre-recorded video presentation is currently available on demand by visiting https://www.glaucoma360-2021.org/page/1704365/video-on-demand.
About the Retinal and Optic Nerve Disease Clinical Programs
Noveome’s multi-target platform biologic and lead product, ST266, is the first potential therapeutic focused on treating the underlying nerve degeneration that occurs in glaucoma through an innovative, non-invasive, targeted intranasal device to deliver ST266 directly to the retina and optic nerve by-passing the blood-brain barrier. Noveome is currently conducting a Phase 1 open-label clinical trial to establish the safety of ST266 by intranasal delivery. Thus far, no drug-related serious adverse events and no pattern of safety concerns have been observed. The trial is expected to be completed in Q1 2021.
About Noveome Biotherapeutics, Inc.
Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. In addition to the Phase 1 open label clinical trial to establish the safety of intranasal ST266 described above, Noveome has launched a program to test ST266 as a treatment for the severe inflammatory response seen in COVID-19 infection as well as the post-COVID-19 symptoms experienced by many COVID-19 patients. Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 in healing persistent corneal epithelial defects (PEDs) and is currently planning follow-up clinical studies to further characterize the efficacy and safety of ST266 for the treatment of PEDs. For more information, visit www.noveome.com.